post-antibiotic effect of orbifloxacin against escherichia coli and pseudomonas aeruginosa isolates from dogs抗生素orbifloxacin效应对大肠杆菌和铜绿假单胞菌分离株的狗.pdfVIP

Harada et al. Acta Veterinaria Scandinavica 2012, 54:16 /content/54/1/16 BRIEF COMMUNICATION Open Access Post-antibiotic effect of orbifloxacin against Escherichia coli and Pseudomonas aeruginosa isolates from dogs * Kazuki Harada , Takae Shimizu, Yasushi Kataoka and Toshio Takahashi Abstract Orbifloxacin is a fluoroquinolone drug used widely in companion animal medicine. In this study, we firstly determined post-antibiotic effects (PAEs) and post-antibiotic sub-minimum inhibitory concentrations (MIC) effects (PA-SMEs) of orbifloxacin for two strains each of Escherichia coli and Pseudomonas aeruginosa from dogs, and these parameters were compared with those of enrofloxacin. At twice the MIC, the PAEs of orbifloxacin ranged from -0.28-0.93 h (mean, 0.29 h) for E. coli and -0.18-1.18 h (mean, 0.37 h) for P. aeruginosa. These parameters were not significantly different for E. coli and shorter for P. aeruginosa, compared to enrofloxacin (P 0.05). Continued exposure to 0.1, 0.2, and 0.3 the MIC of orbifloxacin resulted in average PA-SMEs of 0.55, 1.11, and 2.03 h, respectively, for E. coli, and 1.04, 1.40, and 2.47 h, respectively, for P. aeruginosa. These PA-SMEs, which had no significant differences with those of enrofloxacin, were significantly longer than the corresponding PAEs (P 0.05). These results suggest that the PA-SME of orbifloxacin for E. coli and P. aeruginosa can be meaningfully prolonged by increase of sub-MICs. Findings growth is suppressed by sub-MICs, and has not been Orbifloxacin is a fluoroquinolone developed for use in investigated for all veterinary fluoroquinolones, includ- companion animal medicine. This antimicrobial agent ing orbifloxacin. In this study, we examined the in vi